SecBot SecBot

ANGO

ANGIODYNAMICS INC
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001275187 Healthcare & Medical Devices
$12.26 +0.09 (+0.74%)
Oct 27 4:00 PM ET · prev $12.17
Market cap
$520.0M
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$19.00
+55% · range $17.00–24.00
1 year
−0.2%
from $12.29 · Oct 28
30 days
−21.1%
from $15.54
52-week range
$9.70–16.13
−24% from high · low Apr 7
Avg volume 20D
1.08M
Oct 8 spike 3.06M
Short interest
1.92M
≈4.6% of shares · +48.0%
Days to cover
1.5
at average volume
Insider net
−$344.0K
0 buyers · 1 seller · since Jul 15
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/4
Strongest BULLISH AngioDynamics reported Q1 FY2027 results with net sales of $80.9M (+6.9% YoY), beating revenue consensus of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $344.0K.

  • InstitutionsMIXED

    Q2 2026: 14 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +48.0% to 1.92M shares. 1.5 days to cover, ≈4.6% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYCE & ASSOCIATES LPADD1,969,835$25.6M
STATE STREET CORPTRIM958,167$12.5M
BANK OF AMERICA CORP /DE/TRIM345,143$4.5M
JPMORGAN CHASE & CODOUBLED220,775$2.9M
Orion Porfolio Solutions, LLCADD185,844$2.4M
Connor, Clark & Lunn Investment Management Ltd.TRIM121,273$1.6M
SEI INVESTMENTS COTRIM117,269$1.5M
UBS Group AGNEAR_EXIT84,187$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +55%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 9, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Jul 15, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 15, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$344.0K
sold · 1 insider
DateInsiderTypeValue
Jul 30, 2026
Nighan Warren JR
SVP Quality and Regulatory
SELL$344.0K
Jul 22, 2026
Campbell Chad Thomas
SVP/GM, Vascular Access
EXERCISE6,466 sh
Jul 22, 2026
Campbell Chad Thomas
SVP/GM, Vascular Access
TAX W/H$32.2K
Jul 22, 2026
Trowbridge Stephen A
EVP and CFO
EXERCISE16,296 sh
Jul 22, 2026
Campbell Chad Thomas
SVP/GM, Vascular Access
EXERCISE22,768 sh
Jul 22, 2026
Nighan Warren JR
SVP Quality and Regulatory
EXERCISE5,694 sh
Jul 22, 2026
Piccinini Laura
SVP International
EXERCISE8,047 sh
Jul 22, 2026
Trowbridge Stephen A
EVP and CFO
EXERCISE57,381 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.09-$0.10–-$0.07-50.0%$83.2M
Current FY-$0.28-$0.29–-$0.27-5.0%$337.7M
Next FY-$0.11-$0.15–-$0.06-151.8%$354.9M

Short side

FINRA· Oct 15, 2026
1,916,701
shares short
+48.0%
vs prior settlement
1.5
days to cover
≈4.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Short interest report
Short Interest: ANGO up 48% to 1.9M shares
Settlement 2026-10-15 | Days to cover: 1.46 | ≈4.56% of shares outstanding (est.)
Oct 8, 2026 SEC
AngioDynamics filed DEFA14A definitive additional proxy soliciting materials on October 8, 2026, in connection with…
DEFA14A — Impact 4/10
Oct 8, 2026 SEC
AngioDynamics filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval for the…
DEF 14A — Impact 4/10
Oct 8, 2026 SEC
AngioDynamics reported Q1 FY2027 results with net sales of $80.9M (+6.9% YoY), beating revenue consensus of $84.3M by…
8-K — Impact 6/10
Jul 30, 2026 Insider
Nighan Warren JR sold 23,370 shares
SVP Quality and Regulatory @ $14.72 ($344.0K)
Jul 22, 2026 Insider
Campbell Chad Thomas acquired via exercise 6,466 shares
SVP/GM, Vascular Access
Jul 22, 2026 Insider
Campbell Chad Thomas surrendered for taxes 2,330 shares
SVP/GM, Vascular Access @ $13.82 ($32.2K)
Jun 30, 2026 Inst.
ROYCE & ASSOCIATES LP — ADD
1,969,835 shares ($25.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Short interest
Short Interest: ANGO up 48% to 1.9M shares
Settlement 2026-10-15 | Days to cover: 1.46 | ≈4.56% of shares outstanding (est.)
Oct 8, 2026
Earnings result
ANGO Q1 2027 Earnings: EPS $-0.04 (+65.4% vs est)
Oct 1, 2026
Earnings date
ANGO Q1 2027 Earnings Scheduled — 2026-10-01
Jul 14, 2026
Earnings date
ANGO Q4 2026 Earnings After Market Close — 2026-07-14
Jun 30, 2026
Short interest
Short Interest: ANGO down 23% to 1.4M shares
Settlement 2026-06-30 | Days to cover: 2.89 | ≈3.29% of shares outstanding (est.)

SecBot reports

6 filings · 3 bullish · 0 bearish · 3 neutral
All ANGO filing & press-release reports (6)